Trial *
Publication Guvenmez O, J Popul Ther Clin Ph (2020) (published paper)
Dates: 2020-02-01 to 2020-03-31
Funding: No specific funding (The authors declare that there is no financial support for this article.)
Conflict of interest: No
Methods | |
RCT Blinding: | |
Location :
Single center / Turkey Follow-up duration (days): 6 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Lincomycin 600 mg IV twice a day for 5 days Azithromycin 500 mg orally for the first day, followed by 250 mg orally for the next 4 days |
|
Control
| |
Participants | |
Randomized participants : Lincomycin =12 Azithromycin=12 | |
Characteristics of participants N= 24 Mean age : NR 15 males Severity : Mild: n=0 / Moderate: n=24 / Severe: n=0 Critical: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register NR | |
In the report NR | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Yes |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment | Only the published article was used in data extraction and risk of bias assessment. No primary outcome was specified in the report although one outcome measure was reported in detail (negative RT-PCR) and can be assumed to be the primary outcome. No study protocol or registration was available, so we cannot determine whether or not the target sample size was achieved, there was a change from the trial registration in the intervention and control treatment or the primary and secondary outcomes. Very few baseline characteristics were reported, and no details on comorbidities were reported. |